Working… Menu

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial) (EXACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04125732
Recruitment Status : Recruiting
First Posted : October 14, 2019
Last Update Posted : April 1, 2021
Information provided by (Responsible Party):
XyloCor Therapeutics, Inc.

Brief Summary:
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Ischemia Angina Refractory Cardiovascular Diseases Heart Diseases Biological: AdVEGFXC1 Phase 1 Phase 2

Detailed Description:
This is a Phase 1/2, first-in-human, multicenter, open-label, single arm dose escalation trial of XC001. Approximately 12 subjects (N=3 per cohort) who have refractory angina will be enrolled into 4 ascending dose groups, followed by an expansion of the highest tolerated dose with 32 additional subjects. XC001 will be administered by a transthoracic epicardial procedure. Safety will be the focus for the initial 6 months after XC001 administration followed by one safety focused telephone evaluation at Month 12.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris
Actual Study Start Date : January 24, 2020
Estimated Primary Completion Date : January 31, 2022
Estimated Study Completion Date : July 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angina

Arm Intervention/treatment
Experimental: AdVEGFXC1 at 1x10^9 vp Biological: AdVEGFXC1
AdVEGFXC1 at one of 4 doses
Other Name: XC001

Experimental: AdVEGFXC1 at 1x10^10 vp Biological: AdVEGFXC1
AdVEGFXC1 at one of 4 doses
Other Name: XC001

Experimental: AdVEGFXC1 at 4x10^10 vp Biological: AdVEGFXC1
AdVEGFXC1 at one of 4 doses
Other Name: XC001

Experimental: AdVEGFXC1 at 1x10^11 vp Biological: AdVEGFXC1
AdVEGFXC1 at one of 4 doses
Other Name: XC001

Primary Outcome Measures :
  1. Primary Endpoint (adverse events) [ Time Frame: 6 months ]
    Safety, as assessed by adverse events and serious adverse events

Secondary Outcome Measures :
  1. Secondary Endpoint (Exercise tolerance test) [ Time Frame: 6 months ]
    Exercise tolerance test

  2. Secondary Endpoint (Seattle Angina Questionnaire) [ Time Frame: 6 months ]
    Seattle Angina Questionnaire

  3. Secondary Endpoint (Canadian Cardiovascular Society angina class) [ Time Frame: 6 months ]
    Canadian Cardiovascular Society angina class

  4. Secondary Endpoint (Angina episodes) [ Time Frame: 6 months ]
    Angina episodes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females, age 18 to 80 years
  • Diagnosis of chronic angina due to obstructive coronary artery disease that is refractory to drug therapy and unsuitable for revascularization via coronary artery bypass graft or percutaneous coronary intervention
  • Angina class II-IV based on Canadian Cardiovascular Society Classification of Angina Pectoris
  • Adequate hematologic (hemoglobin ≥ 10 g/dL, absolute neutrophil count > 1.2 × 10^3 per μL and platelet count ≥ 75,000 per μL), hepatic (alanine aminotransferase and aspartate aminotransferase ≤ 3 x ULN; total bilirubin ≤ 2 x ULN), and renal function (glomerular filtration rate > 29 mL/minute/1.73 m2)
  • Adequate birth control if of child-bearing potential
  • Must be willing and able to provide informed consent

Exclusion Criteria:

  • ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI) not requiring revascularization, transmural myocardial infarction or cerebral vascular accident within the past 30 days
  • New York Heart Association Function Class III or IV or left ventricular ejection fraction < 25% within the 6 weeks prior to the screening visit
  • HbA1c ≥ 8.5%, SBP <90 or >180 mmHg, DBP >100 mmHg
  • Other concurrent medical conditions that could jeopardize the safety of the subject or objectives of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04125732

Layout table for location contacts
Contact: Mark Peterson 888-290-0081

Layout table for location information
United States, Arizona
Mayo Clinic Recruiting
Phoenix, Arizona, United States, 85054
Contact: Emily Frank         
Principal Investigator: David Fortuin, MD         
United States, California
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Kokil Bakshi         
Principal Investigator: Brian Kim, MD         
United States, District of Columbia
MedStar Washington Hospital Center Not yet recruiting
Washington, District of Columbia, United States, 20010
Contact: Michelle Deville         
Principal Investigator: Jeff Cohen, MD         
United States, Florida
Cardiology Research Associates Recruiting
Daytona Beach, Florida, United States, 32117
Contact: Lauraine Crandall         
Principal Investigator: David Henderson, MD         
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Sarah Long         
Principal Investigator: David Anderson, MD         
United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Jayne Thompson         
Principal Investigator: Mani Daneshmand, MD         
United States, Minnesota
Minneapolis Heart Institute Foundation Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Jacob Jensen         
Principal Investigator: Jay Traverse, MD         
United States, New York
Columbia University Withdrawn
New York, New York, United States, 10032
United States, North Carolina
Duke University Recruiting
Durham, North Carolina, United States, 27710
Contact: Jennifer Andrews         
Principal Investigator: Tom Povsic, MD         
United States, Ohio
The Christ Hospital / The Lindner Research Center Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Monica Kishman         
Principal Investigator: Tim Henry, MD         
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Lindsey Piazza         
Principal Investigator: Faisal Bakaeen, MD         
The Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Michael Johnson         
Principal Investigator: Nahush Mokadam, MD         
United States, Texas
Houston Methodist Recruiting
Houston, Texas, United States, 77030
Contact: Saba Khan         
Principal Investigator: Tom MacGillivray, MD         
Texas Heart Institute Not yet recruiting
Houston, Texas, United States, 77030
Contact: Emerson Perin, MD         
Principal Investigator: Emerson Perin, MD         
United States, Washington
University of Washington Not yet recruiting
Seattle, Washington, United States, 98195
Contact: Kenta Nakamura, MD         
Principal Investigator: Kenta Nakamura, MD         
Sponsors and Collaborators
XyloCor Therapeutics, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: XyloCor Therapeutics, Inc. Identifier: NCT04125732    
Other Study ID Numbers: XC001-1001
First Posted: October 14, 2019    Key Record Dates
Last Update Posted: April 1, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by XyloCor Therapeutics, Inc.:
Refractory angina
Coronary Artery Disease
Gene Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Angina Pectoris
Arterial Occlusive Diseases
Vascular Diseases
Pathologic Processes
Chest Pain
Neurologic Manifestations